Ergoteles’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ergoteles’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,499	Closed	-$338K	–	1623
2023 Q1	$338K	Sell	10,499 -42,579	-80%	-$1.33M	0.01%	860
2022 Q4	$980K	Buy	53,078 +26,369	+99%	+$603K	0.04%	468
2022 Q3	$721K	Buy	+26,709	New	+$542K	0.03%	625

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's RVNC Position: Q2 2023 in Review

Ergoteles sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 10,499 shares — an estimated $338K sold.

Ergoteles first reported a position in RVNC in Q3 2022 and held it in 3 quarters. The position peaked at $980K in Q4 2022. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

Ergoteles reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 10,499 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $338K.
Ergoteles first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 3 quarters.
Ergoteles's Revance Therapeutics, Inc. position peaked at $980K in Q4 2022.
215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.